172 related articles for article (PubMed ID: 32883642)
1. New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
Nalli M; Armijos Rivera JI; Masci D; Coluccia A; Badia R; Riveira-Muñoz E; Brambilla A; Cinquina E; Turriziani O; Falasca F; Catalano M; Limatola C; Esté JA; Maga G; Silvestri R; Crespan E; La Regina G
Eur J Med Chem; 2020 Dec; 208():112696. PubMed ID: 32883642
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.
Zhao T; Meng Q; Kang D; Ji J; De Clercq E; Pannecouque C; Liu X; Zhan P
Eur J Med Chem; 2019 Nov; 182():111619. PubMed ID: 31434039
[TBL] [Abstract][Full Text] [Related]
3. Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
Famiglini V; La Regina G; Coluccia A; Pelliccia S; Brancale A; Maga G; Crespan E; Badia R; Riveira-Muñoz E; Esté JA; Ferretti R; Cirilli R; Zamperini C; Botta M; Schols D; Limongelli V; Agostino B; Novellino E; Silvestri R
J Med Chem; 2014 Dec; 57(23):9945-57. PubMed ID: 25418038
[TBL] [Abstract][Full Text] [Related]
4. Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
Famiglini V; La Regina G; Coluccia A; Masci D; Brancale A; Badia R; Riveira-Muñoz E; Esté JA; Crespan E; Brambilla A; Maga G; Catalano M; Limatola C; Formica FR; Cirilli R; Novellino E; Silvestri R
J Med Chem; 2017 Aug; 60(15):6528-6547. PubMed ID: 28628334
[TBL] [Abstract][Full Text] [Related]
5. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
[TBL] [Abstract][Full Text] [Related]
6. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
[TBL] [Abstract][Full Text] [Related]
7. Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
La Regina G; Coluccia A; Brancale A; Piscitelli F; Gatti V; Maga G; Samuele A; Pannecouque C; Schols D; Balzarini J; Novellino E; Silvestri R
J Med Chem; 2011 Mar; 54(6):1587-98. PubMed ID: 21366296
[TBL] [Abstract][Full Text] [Related]
8. Indolyl aryl sulfones (IASs): development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug resistant mutants.
Silvestri R; Artico M
Curr Pharm Des; 2005; 11(29):3779-806. PubMed ID: 16305512
[TBL] [Abstract][Full Text] [Related]
9. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.
Xu S; Song S; Sun L; Gao P; Gao S; Ma Y; Kang D; Cheng Y; Zhang X; Cherukupalli S; De Clercq E; Pannecouque C; Liu X; Zhan P
Bioorg Med Chem; 2022 Jan; 53():116531. PubMed ID: 34890994
[TBL] [Abstract][Full Text] [Related]
10. New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
Famiglini V; La Regina G; Coluccia A; Pelliccia S; Brancale A; Maga G; Crespan E; Badia R; Clotet B; Esté JA; Cirilli R; Novellino E; Silvestri R
Eur J Med Chem; 2014 Jun; 80():101-11. PubMed ID: 24769348
[TBL] [Abstract][Full Text] [Related]
11. Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide.
De Martino G; La Regina G; Ragno R; Coluccia A; Bergamini A; Ciaprini C; Sinistro A; Maga G; Crespan E; Artico M; Silvestri R
Antivir Chem Chemother; 2006; 17(2):59-77. PubMed ID: 17042328
[TBL] [Abstract][Full Text] [Related]
12. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
Huang B; Li C; Chen W; Liu T; Yu M; Fu L; Sun Y; Liu H; De Clercq E; Pannecouque C; Balzarini J; Zhan P; Liu X
Eur J Med Chem; 2015 Mar; 92():754-65. PubMed ID: 25626145
[TBL] [Abstract][Full Text] [Related]
13. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
[TBL] [Abstract][Full Text] [Related]
14. New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Brancale A; Piscitelli F; Famiglini V; Cosconati S; Maga G; Samuele A; Gonzalez E; Clotet B; Schols D; Esté JA; Novellino E; Silvestri R
J Med Chem; 2012 Jul; 55(14):6634-8. PubMed ID: 22712652
[TBL] [Abstract][Full Text] [Related]
15. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
Regina GL; Coluccia A; Piscitelli F; Bergamini A; Sinistro A; Cavazza A; Maga G; Samuele A; Zanoli S; Novellino E; Artico M; Silvestri R
J Med Chem; 2007 Oct; 50(20):5034-8. PubMed ID: 17803291
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
[TBL] [Abstract][Full Text] [Related]
17. Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors.
Torti C; Pozniak A; Nelson M; Hertogs K; Gazzard BG
J Antimicrob Chemother; 2001 Jul; 48(1):113-6. PubMed ID: 11418520
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
[TBL] [Abstract][Full Text] [Related]
19. Development of Novel Dihydrofuro[3,4-
Kang D; Sun Y; Feng D; Gao S; Wang Z; Jing L; Zhang T; Jiang X; Lin H; De Clercq E; Pannecouque C; Zhan P; Liu X
J Med Chem; 2022 Feb; 65(3):2458-2470. PubMed ID: 35061384
[TBL] [Abstract][Full Text] [Related]
20. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
Silvestri R; Artico M; De Martino G; La Regina G; Loddo R; La Colla M; Mura M; La Colla P
J Med Chem; 2004 Jul; 47(15):3892-6. PubMed ID: 15239667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
